The PREVENT study, presented at ACC.24, examined more than 1,600 patients with high-risk plaques treated with either preventive PCI or medical therapy alone. Outcomes were much better for the PCI group after two years, but the findings may lead to more questions than answers. 

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

"This was an unneeded burden, which was solely adding to the administrative hassles of medicine," said American Society of Nuclear Cardiology President Larry Phillips.

Interventional cardiologist Foluso Fakorede, MD, opened a practice in rural Mississippi, the epicenter of the PAD and CLI epidemic, to try and reverse the glaring health disparities in that region.

“This is the first time in a very long time that we have a positive study for managing cardiogenic shock,” one cardiologist said. 

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women. 

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

ACC.24 in Atlanta began Saturday, April 6, with a series of late-breaking clinical trials exploring brand new treatment strategies. 

The rumors, it seems, were true. Once the deal is finalized, Shockwave Medical will operate as a business unit within Johnson & Johnson MedTech.

Transcatheter pulmonary valve replacement is still linked to certain risks, researchers noted, but new data confirm it is a safe, effective treatment option for patients with severe PR.